Insider Selling: Progyny (NASDAQ:PGNY) COO Sells $239,450.00 in Stock

Progyny, Inc. (NASDAQ:PGNY) COO Melissa Cummings sold 9,578 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total transaction of $239,450.00. Following the sale, the chief operating officer owned 73,371 shares of the company’s stock, valued at approximately $1,834,275. The trade was a 11.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Up 0.8%

Shares of PGNY stock opened at $24.88 on Friday. The company has a 50 day moving average of $19.06 and a 200-day moving average of $22.03. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $28.75. The firm has a market cap of $1.95 billion, a P/E ratio of 32.31, a PEG ratio of 1.32 and a beta of 0.91.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.03. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company had revenue of $328.50 million during the quarter, compared to analyst estimates of $326.47 million. During the same quarter last year, the business posted $0.17 EPS. Progyny’s quarterly revenue was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, equities analysts expect that Progyny, Inc. will post 1.12 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of PGNY. Vanguard Group Inc. boosted its holdings in Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock valued at $217,484,000 after purchasing an additional 235,513 shares during the period. State Street Corp boosted its holdings in Progyny by 1.5% in the 4th quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after purchasing an additional 44,642 shares during the period. Fort Washington Investment Advisors Inc. OH boosted its holdings in Progyny by 46.9% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after purchasing an additional 859,289 shares during the period. Wellington Management Group LLP boosted its holdings in Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after purchasing an additional 545,431 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research note on Friday, March 27th. Canaccord Genuity Group upgraded shares of Progyny from a “hold” rating to a “buy” rating and lifted their price objective for the company from $19.00 to $30.00 in a research note on Tuesday. Citizens Jmp lifted their price objective on shares of Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research note on Monday, May 11th. Barclays lifted their price objective on shares of Progyny from $23.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price objective on shares of Progyny in a research note on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $29.55.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.